In a recent post we discussed the results of the Exenatide clinical trial from last year, and looked at some further analysis of the data, which hinted at the possibility that the drug may be having additional benefits (Click here to read that post).
The researchers behind the Exenatide study have now published the results of a second deep dive into the data and found something potentially very interesting and useful: they may have identified certain characteristics of those participants in the study who responded the best to the drug.
The researchers are quick to point out that this type of post hoc analysis is only conducted for the purpose of generating hypotheses, but it will be interesting to determine if this is finding is validated in further clinical investigations of Exenatide.
In today’s post, we will review the new finding and discuss what they could potentially mean.
Tom Isaacs. Source: GrannyButtons
For most of the Parkinson’s community, Tom Isaacs requires no introduction.
In 1996 – at just 27-years of age – the London-based surveyor was diagnosed with Parkinson’s. After dealing with the initial shock of it all, Tom embraced his situation and became a committed, (utterly) tireless activist. He first walked the entire coastline of the UK to raise money and awareness for Parkinson’s. His book, “Shake well before use“, discusses that trip and adapting to life with Parkinson’s. It is a fantastic read.
And upon returning from his epic walk, he (along with three others) founded and set up the Cure Parkinson’s Trust.
It is pretty safe to say that beyond Michael J Fox and Muhammad Ali, Tom was one of the most impactful members of the Parkinson’s community on marshaling scientific research efforts to find a cure for Parkinson’s.
And he did it all with style and humour:
This was a video of Tom in 2009, talking about life with Parkinson’s:
His passing last year was a terrible loss to the community, and this month, the European Journal of Neuroscience has a special tribute edition dedicated to the memory of Tom.
One of the research reports in that issue involves a study that was very close to Tom’s heart: The Exenatide study.
And the report provides some very interesting new results based on re-analysis of the results of the clinical study.
What does the new report say?